FDA Green-lights Kymera Therapeutics’ IND Application for Its Oral STAT6 Degrader
The U.S. Food and Drug Administration (FDA) has cleared Kymera Therapeutics, Inc.’s Investigational New Drug (IND) application for KT-621. KT-621 is an investigational first-in-class once daily, oral STAT6 degrader with dupilumab-like activity in preclinical models and the potential to address multiple allergic and atopic diseases including atopic dermatitis, asthma, and chronic obstructive pulmonary disease, among […]